DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Currency in USD	2025
Operating Income	911.80 Million
Income Before Tax	1.09 Billion
Income Tax Expense	252.10 Million
Net Income	836.30 Million
Eps	2.14
Epsdiluted	2.09
Weighted Average Shs Out	390.20 Million
Weighted Average Shs Out Dil	405.50 Million
Research And Development Expenses	599.10 Million
Selling General And Administrative Expenses	1.29 Billion
Depreciation And Amortization	251.80 Million
Interest Expense	18.30 Million
Interest Income	N/A
Net Interest Income	N/A
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	2.80 Billion
Ebitda	1.16 Billion

DexCom, Inc. Annual Reports (10-K)